• On April 7 2015, Coquí Pharma announced the completion of the schematic design of its medical isotope production facility.
  • In January 2015, Coquí Pharma announced it had completed a transaction with the University of Florida Foundation for a 25-acre parcel of land on which it would build its medical isotope production facility. The land is located within Progress Corporate Park in Alachua County, Fla.
  • On November 20, 2014, Coquí Pharma signed a contract with Argentine nuclear engineering firm INVAP to design its Medical Isotope Production Facility (MIPF)  in Alachua, Fla. Coquí’s MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia. Click here to view a press release on the signing.
  • On October 23, 2014, the National Nuclear Security Administration (NNSA) included Coquí RadioPharmaceuticals as an organization in the United States working to develop the ability to produce non-Highly Enriched Uranium-based Mo-99, according to the NNSA Fact Sheet titled “NNSA Works to Establish a Reliable Supply of Mo-99 Produced Without Highly Enriched Uranium.” Coquí’s efforts are listed as complementary to domestic and international efforts to ensure a reliable supply of Mo-99 produced without HEU
  • On August 12, 2014, Coquí presents its updated Permit Application Status & Licensing Strategy to the Nuclear Regulatory Commission. Click here to view the meeting report.
  • On August 3, 2014, Coquí attends the National Organization of Test, Research & Training Reactor (“TRTR”) conference in Portland, Oregon, and participates as a presenter on its efforts as a Mo-99 producer and future TRTR.
  • On July 22, 2014, Coquí meets at INVAP headquarters in Bariloche, Argentina, with Enercon to advance and discuss various topics, pertaining to the licensing of the facility.
  • The week of June 24, 2014, Coquí attends the Department of Energy’s National Nuclear Security Administration 2014 Mo-99 Topical Meeting in Washington, D.C., organized by Argonne National Laboratory and presents the status of its facility.
  • In June 2014, Coquí begins work on the preliminary safety analysis report (“PSAR”) required for licensing of the facility.
  • On May 8, 2014, the Report to the Nuclear Science Advisory Committee Review of the NNSA GTRI Mo‐99 Program is published disclosing that none of the cooperative agreement partners (CA), Coquí’s competitors, achieved the original goal of 3,000, 6-day Ci/week by the end of 2013. The report cites that although the specific deadlines for technology applications are not being met, one of the four CA efforts is making substantial progress, but less so with the other active CAs. The other two projects have ceased work and therefore cannot be considered successful.
  • On April 22, 2014, a Category 1 public meeting is held between Coquí and the Nuclear Regulatory Commission (NRC) staff at NRC Headquarters. The purpose of the meeting is for Coquí to provide the NRC with more information on topics relating to the status of the Medical Isotope Production Facility (MIPF) project, specifically the environmental report and the preliminary safety analysis report (PSAR). Click here to view the meeting report.
  • On March 11, 2014, Coquí attends the Regulatory Information Conference (RIC) hosted by the NRC on various topics including medical radioisotope production efforts to establish a reliable domestic supply of Mo-99.
  • On February 26, 2014, Coquí participates in the Nuclear Science Advisory Committee (NSAC) meeting to Subcommittee to provide an initial assessment on the implementation of the American Medical Isotopes Production Act of 2012, basically evaluating the performance of the National Nuclear Security Agency’s (NNSA) implementation of the Act. Coquí presents further comments in addition to its written response.
  • On February 10, 2014, Coquí provides its response letter to the Nuclear Science Advisory Committee (NSAC) request for input on the initial assessment on the implementation of the American Medical Isotopes Production Act of 2012.
  • In February 2014, work on the environmental study for the selected site granted by the University of Florida Foundation began.
  • On January 2, 2013, the National Defense Authorization Act, which includes the American Medical Isotopes Production Act is signed into law as H.R. 4310.
  • On December 7, 2012, the Company submits to the NRC the Phase 1 Site Assessment along with a public letter on our status.
  • On August 12 and December 23, 2012, the Nuclear Energy Agency (NEA) and Organization of Economic Co-operation and Development (OECD) publishes an article “A Supply and Demand Update of the Molybdenum 99 Market”, in which Coqui Pharma is mentioned.
  • On June 7, 2012, The White House, Office of the Press Secretary, releases “Fact Sheet: Encouraging Reliable Supplies of Molybdenum-99 Produced without Highly Enriched Uranium.”
  • On May 11, 2012, the Company presents its licensing status in a public hearing at the Nuclear Regulatory Commission (NRC) where its competitors also presented their licensing status. In the hearing, the NRC acknowledges that of the three potential Mo-99 producers, only Coqui Pharma has a clear path to licensing because it uses proven technology. Since then, one of the competitors has removed their submission.
  • In February 2012, University of Florida, Foundation grants the Company a site for construction of the Medical Isotope Production Facility (MIPF).